Preventive antiepileptic treatment in infants with tuberous sclerosis complex (TSC) modifies the natural history of epilepsy, reducing the risk and severity, according to new study findings.
About 70-90% of children with TSC develop epilepsy, which is often resistant to medication. In the multicenter EPISTOP trial, researchers compared the efficacy and safety of preventive versus conventional antiepileptic treatment in infants with TSC.
Presenting at ICNA/CNS 2020, Dr Katarzyna Kotulska-Jozwiak from the Children’s Memorial Health Institute, in Warsaw, Poland, said 94 infants with TSC without a seizure history were followed until 2 years of age with monthly video EEG.
They received antiepileptic treatment with vigabatrin either as conventional treatment (started after the first electrographic of clinical seizure) or preventively (if epileptiform EEG activity before seizures was detected).